What Factors Propelled The Growth Of The Vascular Dementia Market In The Past?
The vascular dementia market has seen considerable growth due to a variety of factors.
• In recent times, significant growth has been witnessed in the vascular dementia market size. The market is projected to escalate from $2.92 billion in 2024 to $3.27 billion in 2025, indicating a compound annual growth rate (CAGR) of 12.1%.
This substantial growth during the past years can be accredited to factors such as an increase in healthcare spending, a surge in patient diagnoses of vascular dementia, an increase in healthcare professionals, development in public health campaigns, and a higher prevalence of diabetes.
What Are the Future Growth Projections for the Vascular Dementia Market?
The vascular dementia market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for vascular dementia is anticipated to experience swift expansion in the coming years, reaching a valuation of $5.11 billion in 2029, growing at a compound annual growth rate (CAGR) of 11.8%.
This growth in the prediction stretch is due to factors such as escalating awareness about vascular dementia, increased investment in healthcare, the expanding elderly population, and the increased incidence of cardiovascular diseases and high blood pressure. The forecast period is also expected to provide major trends such as advancements in technology, customized care arrangements, telemedicine, gene therapy, and artificial intelligence.
What Are The Leading Drivers Of Growth In The Vascular Dementia Market?
The predicted growth of the vascular dementia market originates from the escalating incidence of cardiovascular disease. These conditions encompass a myriad of disorders that impact the heart and blood vessels, such as coronary artery disease, heart failure, arrhythmias, and hypertension. Increased rates of cardiovascular diseases are spurred on by factors like poor lifestyle habits, unhealthy diets, lack of physical activity, heightened stress levels, the aging population, and the growth of risk elements like obesity, diabetes, and hypertension. Cardiovascular disease amplifies the chances of vascular dementia by negatively affecting the brain's blood flow, resulting in cognitive decline and brain cell damage due to the decrease in oxygen and nutrient delivery. For example, in September 2024, data released by the UK-based cardiovascular research charity, the British Heart Foundation, reported that in the UK, nearly 7.6 million individuals suffer from heart and circulation diseases, composing around 4 million males and 3.6 million females coping with these diseases. Consequently, these diseases cause about 27% of all UK deaths, resulting in over 170,000 deaths per year, or approximately 480 deaths every day. This equates to a death every three minutes. Hence, the growing incidence of cardiovascular disease is a key driver in the vascular dementia market's progression.
What Are The Major Segments Within The Vascular Dementia Market?
The vascular dementia market covered in this report is segmented –
1) By Product: Monoclonal Antibodies, Small Molecules, Peptides
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By End User: Hospitals And Clinics, Rehabilitation Centers, Specialty Clinics
Subsegments:
1) By Monoclonal Antibodies: Anti-Amyloid Monoclonal Antibodies, Anti-Tau Monoclonal Antibodies
2) By Small Molecules: Cholinesterase Inhibitors, Glutamate Modulators, Anti-Inflammatory Small Molecules
3) By Peptides: Amyloid-Beta Targeted Peptides, Neuroprotective Peptides, Tau-Targeting Peptides
Pre-Book The Vascular Dementia Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Vascular Dementia Market?
Leading corporations in the vascular dementia market are concentrating their efforts on creating innovative treatments, such as multimodal therapies, to maintain their standing in the market. These multimodal therapies are a blend of various approaches to treatment, including medication, physical therapy and psychological interventions, implemented collectively to effectively treat a condition. As an example, in January 2023, Singapore-based biopharmaceutical firm, Moleac, introduced CognivAiD, a treatment specifically tailored for vascular dementia (VaD), a condition with not many therapeutic alternatives. This product mixes active extracts from ginkgo, ginseng, and saffron, which have been proven to dramatically reduce cognitive deterioration in VaD patients. The distinctive multimodal function of CognivAiD addresses crucial aspects of vascular dementia, including vascular protection, vasoregulation, and neuroinflammation. With robust support from thorough clinical trials and a strong safety profile, CognivAiD emerges as a promising new therapeutic option for those afflicted with VaD.
Who Are the Key Players in the Vascular Dementia Market?
Major companies operating in the vascular dementia market are include:
• Intermountain Healthcare Inc.
• CSPC Ouyi Pharmaceutical Co. Ltd.
• Duke Health
• Massachusetts General Hospital
• Emory Healthcare Inc.
• Apollo Hospitals Enterprise Limited
• Amedisys Inc.
• Northwestern Memorial HealthCare
• IBS Hospitals Pvt. Ltd.
• Resverlogix Corp.
• ProNeurogen Inc.
• Cyclerion Therapeutics Inc.
• Aribio Inc.
• Pinteon Therapeutics Inc.
• Dementech Neurosciences Ltd.
• Moleac Pte. Ltd.
• Isaac Health Inc.
• Cadabam’s Group of Hospitals
• Alpha Cognition Inc.
• Citi Health
What Is The Most Dominant Region In The Vascular Dementia Market?
North America was the largest region in the vascular dementia market in 2024. The regions covered in the vascular dementia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
